23 recherche sur le mot-clé 'Expressive language'

Expressive language abilities of boys with idiopathic autism spectrum disorder and boys with fragile X syndrome + autism spectrum disorder: Cross-context comparisons / Elizabeth HILVERT in Autism & Developmental Language Impairments, 5 (January-December 2020)  

Public ISBD [article]  inAutism & Developmental Language Impairments > 5 (January-December 2020) Titre : Expressive language abilities of boys with idiopathic autism spectrum disorder and boys with fragile X syndrome + autism spectrum disorder: Cross-context comparisons Type de document : texte imprimé Auteurs : Elizabeth HILVERT, Auteur ; Audra STERLING, Auteur ; Eileen HAEBIG, Auteur ; Laura FRIEDMAN, Auteur Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  fragile X syndrome  expressive language  language sampling Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1177/2396941520912118 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=438 [article] Expressive language abilities of boys with idiopathic autism spectrum disorder and boys with fragile X syndrome + autism spectrum disorder: Cross-context comparisons [texte imprimé] / Elizabeth HILVERT, Auteur ; Audra STERLING, Auteur ; Eileen HAEBIG, Auteur ; Laura FRIEDMAN, Auteur. Langues : Anglais (eng) in Autism & Developmental Language Impairments > 5 (January-December 2020) Mots-clés : Autism spectrum disorder  fragile X syndrome  expressive language  language sampling Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1177/2396941520912118 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=438

Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity / Leonard ABBEDUTO in Journal of Neurodevelopmental Disorders, 12 (2020)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 12 (2020) Titre : Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity Type de document : texte imprimé Auteurs : Leonard ABBEDUTO, Auteur ; Elizabeth BERRY-KRAVIS, Auteur ; Audra STERLING, Auteur ; Stephanie SHERMAN, Auteur ; Jamie O. EDGIN, Auteur ; Andrea MCDUFFIE, Auteur ; Anne HOFFMANN, Auteur ; Debra HAMILTON, Auteur ; Michael NELSON, Auteur ; Jeannie ASCHKENASY, Auteur ; Angela John THURMAN, Auteur Langues : Anglais (eng) Mots-clés : Adolescent  Autistic Disorder/diagnosis  Child  Feasibility Studies  Female  Fragile X Syndrome/therapy  Humans  Language Tests/statistics & numerical data  Male  Outcome Assessment, Health Care  Psychometrics  Reproducibility of Results  Young Adult  Clinical trials  Expressive language  Fragile X syndrome  Outcome measures  treatment  Pharmaceuticals Ltd., Fulcrum Therapeutics, and Lumind to consult on and  implement outcome measures in clinical trials for FXS and Down syndrome. EBK has  received funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren,  Cydan, Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin, Lumos, Ovid, AMO,  Yamo, Ionis, GeneTx, Acadia, Neurogene, Ultragenyx, and  Vtesse/Sucampo/Mallinkcrodt Pharmaceuticals to consult on trial design or  development strategies and/or conduct clinical trials in FXS or other genetic  Neurodevelopmental or neurodegenerative disorders, and from Asuragen Inc. to  develop testing standards for FMR1 testing. AJT has received funding from Fulcrum  Therapeutics to develop outcome measures for FXS. The other authors declare that  they have no competing interests. Index. décimale : PER Périodiques Résumé : BACKGROUND: The evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for treatment research in FXS. We addressed: (a) feasibility, (b) practice effects over two administrations, (c) test-retest reliability over the repeated administrations, and (d) construct validity. We addressed these issues for the full sample as well as for subgroups defined by age, IQ, and ASD status. METHODS: Participants were 106 individuals with FXS between ages 6 and 23 years who had IQs within the range of intellectual disability (IQ < 70). ELS procedures for collecting samples in conversation and narration were followed and analyzed separately. Five measures were derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers): number of C-units per minute (talkativeness), number of different word roots (vocabulary), C-unit length in morphemes (syntax), percentage of C-units containing dysfluency (utterance planning), and percentage of C-units that were fully or partly unintelligible (articulatory quality). ELS procedures were administered twice at 4-week intervals for each participant. Standardized tests and informant reports were administered and provided measures for evaluating construct validity of ELS measures. RESULTS: We found low rates of noncompliance, suggesting the task can be completed meaningfully by most individuals with FXS, although noncompliance was higher for younger, lower IQ, and more autistic participants. Minimal practice effects and strong test-retest reliability over the 4-week interval were observed for the full sample and across the range of ages, IQs, and autism symptom severity. Evidence of convergent construct validity was observed for the measures of vocabulary, syntax, and unintelligibility for the full sample and across the range of IQ and autism symptom severity, but not for participants under age 12. Conversation and narration yielded largely similar results in all analyses. CONCLUSIONS: The findings suggest that the ELS procedures are feasible and yield measures with adequate psychometric properties for a majority of 6 to 23 years with FXS who have ID. The procedures work equally well regardless of level of ID or degree of ASD severity. The procedures, however, are more challenging and have somewhat less adequate psychometric properties for individuals with FXS under age 12. En ligne : https://dx.doi.org/10.1186/s11689-020-09313-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity [texte imprimé] / Leonard ABBEDUTO, Auteur ; Elizabeth BERRY-KRAVIS, Auteur ; Audra STERLING, Auteur ; Stephanie SHERMAN, Auteur ; Jamie O. EDGIN, Auteur ; Andrea MCDUFFIE, Auteur ; Anne HOFFMANN, Auteur ; Debra HAMILTON, Auteur ; Michael NELSON, Auteur ; Jeannie ASCHKENASY, Auteur ; Angela John THURMAN, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 12 (2020) Mots-clés : Adolescent  Autistic Disorder/diagnosis  Child  Feasibility Studies  Female  Fragile X Syndrome/therapy  Humans  Language Tests/statistics & numerical data  Male  Outcome Assessment, Health Care  Psychometrics  Reproducibility of Results  Young Adult  Clinical trials  Expressive language  Fragile X syndrome  Outcome measures  treatment  Pharmaceuticals Ltd., Fulcrum Therapeutics, and Lumind to consult on and  implement outcome measures in clinical trials for FXS and Down syndrome. EBK has  received funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren,  Cydan, Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin, Lumos, Ovid, AMO,  Yamo, Ionis, GeneTx, Acadia, Neurogene, Ultragenyx, and  Vtesse/Sucampo/Mallinkcrodt Pharmaceuticals to consult on trial design or  development strategies and/or conduct clinical trials in FXS or other genetic  Neurodevelopmental or neurodegenerative disorders, and from Asuragen Inc. to  develop testing standards for FMR1 testing. AJT has received funding from Fulcrum  Therapeutics to develop outcome measures for FXS. The other authors declare that  they have no competing interests. Index. décimale : PER Périodiques Résumé : BACKGROUND: The evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for treatment research in FXS. We addressed: (a) feasibility, (b) practice effects over two administrations, (c) test-retest reliability over the repeated administrations, and (d) construct validity. We addressed these issues for the full sample as well as for subgroups defined by age, IQ, and ASD status. METHODS: Participants were 106 individuals with FXS between ages 6 and 23 years who had IQs within the range of intellectual disability (IQ < 70). ELS procedures for collecting samples in conversation and narration were followed and analyzed separately. Five measures were derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers): number of C-units per minute (talkativeness), number of different word roots (vocabulary), C-unit length in morphemes (syntax), percentage of C-units containing dysfluency (utterance planning), and percentage of C-units that were fully or partly unintelligible (articulatory quality). ELS procedures were administered twice at 4-week intervals for each participant. Standardized tests and informant reports were administered and provided measures for evaluating construct validity of ELS measures. RESULTS: We found low rates of noncompliance, suggesting the task can be completed meaningfully by most individuals with FXS, although noncompliance was higher for younger, lower IQ, and more autistic participants. Minimal practice effects and strong test-retest reliability over the 4-week interval were observed for the full sample and across the range of ages, IQs, and autism symptom severity. Evidence of convergent construct validity was observed for the measures of vocabulary, syntax, and unintelligibility for the full sample and across the range of IQ and autism symptom severity, but not for participants under age 12. Conversation and narration yielded largely similar results in all analyses. CONCLUSIONS: The findings suggest that the ELS procedures are feasible and yield measures with adequate psychometric properties for a majority of 6 to 23 years with FXS who have ID. The procedures work equally well regardless of level of ID or degree of ASD severity. The procedures, however, are more challenging and have somewhat less adequate psychometric properties for individuals with FXS under age 12. En ligne : https://dx.doi.org/10.1186/s11689-020-09313-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language sampling / Angela John THURMAN in Journal of Neurodevelopmental Disorders, 13 (2021)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 13 (2021) Titre : Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language sampling Type de document : texte imprimé Auteurs : Angela John THURMAN, Auteur ; Jamie O. EDGIN, Auteur ; Stephanie L SHERMAN, Auteur ; Audra STERLING, Auteur ; Andrea MCDUFFIE, Auteur ; Elizabeth BERRY-KRAVIS, Auteur ; Debra HAMILTON, Auteur ; Leonard ABBEDUTO, Auteur Langues : Anglais (eng) Mots-clés : Adolescent  Adult  Child  Child, Preschool  Down Syndrome  Feasibility Studies  Humans  Language  Outcome Assessment, Health Care  Reproducibility of Results  Young Adult  Clinical trials  Down syndrome  Expressive language  Expressive language sampling  Outcome measures  Psychometrics  Treatment  Pharmaceuticals Ltd., Fulcrum Therapeutics, and Lumind to consult on and  implement outcome measures in clinical trials for FXS and DS. EBK has received  funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan,  Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin, Lumos, Ovid, AMO, Yamo,  Ionis, GeneTx, Acadia, Neurogene, Ultragenyx, and Vtesse/Sucampo/Mallinkcrodt  Pharmaceuticals to consult on trial design or development strategies and/or  conduct clinical trials in FXS or other genetic neurodevelopmental or  neurodegenerative disorders, and from Asuragen Inc. to develop testing standards  for FMR1 testing. AJT has received funding from Fulcrum Therapeutics to develop  outcome measures for FXS. The other authors declare that they have no competing  interests. Index. décimale : PER Périodiques Résumé : BACKGROUND: The purpose of this study was to evaluate expressive language sampling (ELS) as a procedure for generating spoken language outcome measures for treatment research in Down syndrome (DS). We addressed (a) feasibility, (b) practice effects across two short-term administrations, (c) test-retest reliability across two short-term administrations, (d) convergent and discriminant construct validity, and (e) considered comparisons across the conversation and narration contexts. METHOD: Participants were 107 individuals with DS between 6 and 23 years of age who presented with intellectual disability (IQ < 70). The utility of ELS procedures designed to collect samples of spoken language in conversation and narration were evaluated separately. Variables of talkativeness, vocabulary, syntax, utterance planning, and articulation quality, derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers), were considered. A 4-week interval was used to assess practice effects and test-retest reliability. Standardized direct assessments and informant report measures were collected to evaluate construct validity of the ELS variables. RESULTS: Low rates of noncompliance were observed; youth who were under 12 years of age, had phrase-level speech or less, and had a 4-year-old developmental level or less were at particular risk for experiencing difficulty completing the ELS procedures. Minimal practice effects and strong test-retest reliability across the 4-week test-retest interval was observed. The vocabulary, syntax, and speech intelligibility variables demonstrated strong convergent and discriminant validity. Although significant correlations were found between the variables derived from both the conversation and narration contexts, some differences were noted. CONCLUSION: The ELS procedures considered were feasible and yielded variables with adequate psychometric properties for most individuals with DS between 6 and 23 years old. That said, studies of outcome measures appropriate for individuals with DS with more limited spoken language skills are needed. Context differences were observed in ELS variables suggest that comprehensive evaluation of expressive language is likely best obtained when utilizing both contexts. En ligne : https://dx.doi.org/10.1186/s11689-021-09361-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language sampling [texte imprimé] / Angela John THURMAN, Auteur ; Jamie O. EDGIN, Auteur ; Stephanie L SHERMAN, Auteur ; Audra STERLING, Auteur ; Andrea MCDUFFIE, Auteur ; Elizabeth BERRY-KRAVIS, Auteur ; Debra HAMILTON, Auteur ; Leonard ABBEDUTO, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 13 (2021) Mots-clés : Adolescent  Adult  Child  Child, Preschool  Down Syndrome  Feasibility Studies  Humans  Language  Outcome Assessment, Health Care  Reproducibility of Results  Young Adult  Clinical trials  Down syndrome  Expressive language  Expressive language sampling  Outcome measures  Psychometrics  Treatment  Pharmaceuticals Ltd., Fulcrum Therapeutics, and Lumind to consult on and  implement outcome measures in clinical trials for FXS and DS. EBK has received  funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan,  Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin, Lumos, Ovid, AMO, Yamo,  Ionis, GeneTx, Acadia, Neurogene, Ultragenyx, and Vtesse/Sucampo/Mallinkcrodt  Pharmaceuticals to consult on trial design or development strategies and/or  conduct clinical trials in FXS or other genetic neurodevelopmental or  neurodegenerative disorders, and from Asuragen Inc. to develop testing standards  for FMR1 testing. AJT has received funding from Fulcrum Therapeutics to develop  outcome measures for FXS. The other authors declare that they have no competing  interests. Index. décimale : PER Périodiques Résumé : BACKGROUND: The purpose of this study was to evaluate expressive language sampling (ELS) as a procedure for generating spoken language outcome measures for treatment research in Down syndrome (DS). We addressed (a) feasibility, (b) practice effects across two short-term administrations, (c) test-retest reliability across two short-term administrations, (d) convergent and discriminant construct validity, and (e) considered comparisons across the conversation and narration contexts. METHOD: Participants were 107 individuals with DS between 6 and 23 years of age who presented with intellectual disability (IQ < 70). The utility of ELS procedures designed to collect samples of spoken language in conversation and narration were evaluated separately. Variables of talkativeness, vocabulary, syntax, utterance planning, and articulation quality, derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers), were considered. A 4-week interval was used to assess practice effects and test-retest reliability. Standardized direct assessments and informant report measures were collected to evaluate construct validity of the ELS variables. RESULTS: Low rates of noncompliance were observed; youth who were under 12 years of age, had phrase-level speech or less, and had a 4-year-old developmental level or less were at particular risk for experiencing difficulty completing the ELS procedures. Minimal practice effects and strong test-retest reliability across the 4-week test-retest interval was observed. The vocabulary, syntax, and speech intelligibility variables demonstrated strong convergent and discriminant validity. Although significant correlations were found between the variables derived from both the conversation and narration contexts, some differences were noted. CONCLUSION: The ELS procedures considered were feasible and yielded variables with adequate psychometric properties for most individuals with DS between 6 and 23 years old. That said, studies of outcome measures appropriate for individuals with DS with more limited spoken language skills are needed. Context differences were observed in ELS variables suggest that comprehensive evaluation of expressive language is likely best obtained when utilizing both contexts. En ligne : https://dx.doi.org/10.1186/s11689-021-09361-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

Concurrent Social Communication Predictors of Expressive Language in Minimally Verbal Children and Adolescents with Autism Spectrum Disorder / Meredith PECUKONIS in Journal of Autism and Developmental Disorders, 49-9 (September 2019)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 49-9 (September 2019) . - p.3767-3785 Titre : Concurrent Social Communication Predictors of Expressive Language in Minimally Verbal Children and Adolescents with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Meredith PECUKONIS, Auteur ; Daniela PLESA-SKWERER, Auteur ; Brady EGGLESTON, Auteur ; Steven R. MEYER, Auteur ; Helen TAGER-FLUSBERG, Auteur Article en page(s) : p.3767-3785 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Expressive language  Imitation  Joint attention  Minimally verbal  Play Index. décimale : PER Périodiques Résumé : Numerous studies have investigated the predictors of language in pre-verbal toddlers and verbally fluent children with autism spectrum disorder (ASD). The present study investigated the concurrent relations among expressive language and a set of empirically-selected social communication variables-joint attention, imitation, and play-in a unique sample of 37 minimally verbal (MV) children and adolescents with ASD. Results revealed that imitation and play were significantly correlated with expressive language, even when controlling for non-verbal IQ, but joint attention was not. Imitation was the only predictor variable to reach significance within the regression model. Findings demonstrate that predictors of expressive language vary for subpopulations of the autism spectrum, and have broader implications for intervention design for older, MV individuals with ASD. En ligne : http://dx.doi.org/10.1007/s10803-019-04089-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=405 [article] Concurrent Social Communication Predictors of Expressive Language in Minimally Verbal Children and Adolescents with Autism Spectrum Disorder [texte imprimé] / Meredith PECUKONIS, Auteur ; Daniela PLESA-SKWERER, Auteur ; Brady EGGLESTON, Auteur ; Steven R. MEYER, Auteur ; Helen TAGER-FLUSBERG, Auteur . - p.3767-3785. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 49-9 (September 2019) . - p.3767-3785 Mots-clés : Autism spectrum disorder  Expressive language  Imitation  Joint attention  Minimally verbal  Play Index. décimale : PER Périodiques Résumé : Numerous studies have investigated the predictors of language in pre-verbal toddlers and verbally fluent children with autism spectrum disorder (ASD). The present study investigated the concurrent relations among expressive language and a set of empirically-selected social communication variables-joint attention, imitation, and play-in a unique sample of 37 minimally verbal (MV) children and adolescents with ASD. Results revealed that imitation and play were significantly correlated with expressive language, even when controlling for non-verbal IQ, but joint attention was not. Imitation was the only predictor variable to reach significance within the regression model. Findings demonstrate that predictors of expressive language vary for subpopulations of the autism spectrum, and have broader implications for intervention design for older, MV individuals with ASD. En ligne : http://dx.doi.org/10.1007/s10803-019-04089-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=405

Development of fine motor skills is associated with expressive language outcomes in infants at high and low risk for autism spectrum disorder / Boin CHOI in Journal of Neurodevelopmental Disorders, 10-1 (December 2018)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 10-1 (December 2018) . - 14 p. Titre : Development of fine motor skills is associated with expressive language outcomes in infants at high and low risk for autism spectrum disorder Type de document : texte imprimé Auteurs : Boin CHOI, Auteur ; Kathryn A. LEECH, Auteur ; Helen TAGER-FLUSBERG, Auteur ; Charles A. NELSON, Auteur Année de publication : 2018 Article en page(s) : 14 p. Langues : Anglais (eng) Mots-clés : Autism  Early development  Expressive language  Fine motor skills  Infant siblings Index. décimale : PER Périodiques Résumé : BACKGROUND: A growing body of research suggests that fine motor abilities are associated with skills in a variety of domains in both typical and atypical development. In this study, we investigated developmental trajectories of fine motor skills between 6 and 24 months in relation to expressive language outcomes at 36 months in infants at high and low familial risk for autism spectrum disorder (ASD). METHODS: Participants included 71 high-risk infants without ASD diagnoses, 30 high-risk infants later diagnosed with ASD, and 69 low-risk infants without ASD diagnoses. As part of a prospective, longitudinal study, fine motor skills were assessed at 6, 12, 18, and 24 months of age and expressive language outcomes at 36 months using the Mullen Scales of Early Learning. Diagnosis of ASD was determined at the infant's last visit to the lab (18, 24, or 36 months) using the Autism Diagnostic Observation Schedule. RESULTS: Hierarchical linear modeling revealed that high-risk infants who later developed ASD showed significantly slower growth in fine motor skills between 6 and 24 months, compared to their typically developing peers. In contrast to group differences in growth from age 6 months, cross-sectional group differences emerged only in the second year of life. Also, fine motor skills at 6 months predicted expressive language outcomes at 3 years of age. CONCLUSIONS: These results highlight the importance of utilizing longitudinal approaches in measuring early fine motor skills to reveal subtle group differences in infancy between ASD high-risk and low-risk infant populations and to predict their subsequent language outcomes. En ligne : http://dx.doi.org/10.1186/s11689-018-9231-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=386 [article] Development of fine motor skills is associated with expressive language outcomes in infants at high and low risk for autism spectrum disorder [texte imprimé] / Boin CHOI, Auteur ; Kathryn A. LEECH, Auteur ; Helen TAGER-FLUSBERG, Auteur ; Charles A. NELSON, Auteur . - 2018 . - 14 p. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 10-1 (December 2018) . - 14 p. Mots-clés : Autism  Early development  Expressive language  Fine motor skills  Infant siblings Index. décimale : PER Périodiques Résumé : BACKGROUND: A growing body of research suggests that fine motor abilities are associated with skills in a variety of domains in both typical and atypical development. In this study, we investigated developmental trajectories of fine motor skills between 6 and 24 months in relation to expressive language outcomes at 36 months in infants at high and low familial risk for autism spectrum disorder (ASD). METHODS: Participants included 71 high-risk infants without ASD diagnoses, 30 high-risk infants later diagnosed with ASD, and 69 low-risk infants without ASD diagnoses. As part of a prospective, longitudinal study, fine motor skills were assessed at 6, 12, 18, and 24 months of age and expressive language outcomes at 36 months using the Mullen Scales of Early Learning. Diagnosis of ASD was determined at the infant's last visit to the lab (18, 24, or 36 months) using the Autism Diagnostic Observation Schedule. RESULTS: Hierarchical linear modeling revealed that high-risk infants who later developed ASD showed significantly slower growth in fine motor skills between 6 and 24 months, compared to their typically developing peers. In contrast to group differences in growth from age 6 months, cross-sectional group differences emerged only in the second year of life. Also, fine motor skills at 6 months predicted expressive language outcomes at 3 years of age. CONCLUSIONS: These results highlight the importance of utilizing longitudinal approaches in measuring early fine motor skills to reveal subtle group differences in infancy between ASD high-risk and low-risk infant populations and to predict their subsequent language outcomes. En ligne : http://dx.doi.org/10.1186/s11689-018-9231-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=386

Does phonetic repertoire in minimally verbal autistic preschoolers predict the severity of later expressive language impairment? / Jo SAUL in Autism, 24-5 (July 2020)  

Permalink

Exploring receptive and expressive language components at the age of 36 months in siblings at risk for autism spectrum disorder / Eva BRUYNEEL in Research in Autism Spectrum Disorders, 66 (October 2019)  

Permalink

Expressive Dominant Versus Receptive Dominant Language Patterns in Young Children: Findings from the Study to Explore Early Development / D.B. REINHARTSEN in Journal of Autism and Developmental Disorders, 49-6 (June 2019)  

Permalink

Factors associated with receptive and expressive language in autistic children and siblings: A systematic review / Marjolein MUÈS in Autism & Developmental Language Impairments, 9 (January-December 2024)  

Permalink

Language in Low-Functioning Children with Autistic Disorder: Differences Between Receptive and Expressive Skills and Concurrent Predictors of Language / Jarymke MALJAARS in Journal of Autism and Developmental Disorders, 42-10 (October 2012)  

Permalink